Navigation Links
Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Date:10/5/2007

e Efficacy and Safety of Bazedoxifene/Conjugated Estrogens for Treatment of Menopausal Vasomotor Symptoms," which evaluated 332 symptomatic postmenopausal women who, at baseline, experienced seven or more moderate to severe hot flashes per day or 50 or more hot flashes per week were presented. The study showed that, when compared with placebo, bazedoxifene/conjugated estrogens significantly reduced the number and severity of hot flashes. Furthermore, the incidences of breast pain and bleeding were less than 5 percent and did not differ from placebo. The most commonly reported adverse events were headache and joint pain.

Data from another Phase 3 study titled "Effects of the TSEC Bazedoxifene and Conjugated Estrogens on Vulvar/Vaginal Atrophy and Sexual Function in Postmenopausal Women," which evaluated 601 postmenopausal women with moderate to severe vulvar and vaginal atrophy, also were presented. These data showed that bazedoxifene/conjugated estrogens improved symptoms of vulvar and vaginal atrophy, including dryness. In addition, bazedoxifene/conjugated estrogens improved vaginal lubrication, sexual function and menopause-related quality of life, when compared with placebo. The incidences of breast pain and bleeding were less than 5 percent and did not differ from placebo. There were no differences among groups in the incidences of adverse events and discontinuation rates.

"Bazedoxifene/conjugated estrogens, if approved, will be a new and different therapeutic option that has the potential to change the way physicians and their patients treat menopausal symptoms and prevent postmenopausal osteoporosis," says Dr. Constantine.

The efficacy and safety data for bazedoxifene/conjugated estrogens presented at this meeting represents only a portion of the totality of data available at this time.

About Menopause

According to the U.S. Census Bureau, in 2006, there were approximately 20 million women of menopausal age (45-54 years) in the Uni
'/>"/>

SOURCE Wyeth
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...CITY,Nov.24/PRNewswire/-- InfiniteMind ,aSaltLakeC...linevisiontherapyprogrameyeQ,thesoftwareprogramist...thods. ,, eyeQ wasintroducedattheCOVDconferenc...ct,Dr.BradHabermehlbelievesthe eyeQ programaddssig...FlintMichigan.Itallowshispatientstoembedpracticesf...
(Date:11/24/2009)...UGA,Ontario,Nov.24/PRNewswire-FirstCall/--CardioGe...oftechnologyandproductstargetingtheimmunoassaysegm....S.("MerckChimie")isprogressingtothenextphaseofthe...oatedparamagneticBeads("Beads"). ,, Pertheagree...CardioGenicssuppliedMerckChimiewithitsproprietarys...
(Date:11/24/2009)...Nov.24/PRNewswire-Asia-FirstCall/--LotusPharmaceut...mpany")agrowingdeveloperand,producerofprescription...oductsinthePeople,sRepublicChina,todayreporteditwi...pharmaceuticaldelegation. ,, Time:November26-...,Chengdu ,, TheBeijingdelegationfeaturesmoret...
Breaking Medicine Technology:Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 3Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA 2Medicines Top Source of Kids Poisonings 53612 1Medicines Top Source of Kids Poisonings 53612 2Medicines Top Source of Kids Poisonings 53612 3Medicines Top Source of Kids Poisonings 53612 4More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 1More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 2More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 4Connectyx Partners with InstantAmber a Leader in Child Safety and Missing Children Awareness 53606 1Connectyx Partners with InstantAmber a Leader in Child Safety and Missing Children Awareness 53606 2Connectyx Partners with InstantAmber a Leader in Child Safety and Missing Children Awareness 53606 3
... of HEAR Music, NEW YORK, June 30 In the fall of...r people to receive music from artists they,love a...plying the (RED),idea to music this new model will...s and buy life-saving medicine for those living wi...R Music and former Vice President of Music,& Enter...
... -- 10:00 a.m. EDT, 7:00 a.m. PDT ... -- http://www.isispharm.com , SAN DI...) will conduct a conference call at 10:00 a.m. EDT...sults of the TV-1102 clinical trial,and the ATL / ...ced clinical data on TV-1102 demonstrating,positiv...
Other Medicine Technology:(RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa 2(RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa 3Isis Pharmaceuticals Conference Call Notice 2
(Date:11/24/2009)...c.todayannouncedtheacquisitionofRetirementCapitalG...sationandbenefitplanprovidersheadquarteredinSanDie...waukee,Boston,ChicagoandAtlanta.RCGwasfoundedin200...enefitsindustry. ,, "Weareexcitedtoannouncethea...sence,"statesBillPollock,ChairmanandFounderofNIP."...
(Date:11/24/2009)...re/--Dr.NelsonEscobar,aphysicianwiththeMarianjoyMe...Award.TheawardwaspresentedtohimbytheBrainInjuryAss...onOctober30,2009. ,, AccordingtotheBIAofIllinoi...rtiseinaddressingthecomplexneedsofpersonswithbrain...reofhispatientsandtheirfamiliesastheyrebuildtheirl...
(Date:11/24/2009)...CenteneCorporation(NYSE: CNC )todayannouncedthatth...oneoftwoCoordinatedCareOrganizationstoparticipatei...iCAN),acoordinatedcareprogramforMississippiMedicai...ecuteacontractinwhichthecompanywillserveeligibleme...lia). ,, BasedinJackson,Miss.,Magnoliawillworkw...
(Date:11/24/2009)...etween high- and low-volume centers, study found ,...Do hospitals that conduct the most angioplasties n...Maybe not. , Prior research had suggested that ...pening procedures, but a new study involving over ...ls performing more or less equally. , The study...
(Date:11/24/2009)... use but higher costs , , TUESDAY, Nov. ... may contribute to higher Medicaid costs, accordin... used antiplatelet drug clopidogrel (Plavix). ,...te Medicaid programs found that direct-to-consumer...le,s use of the drug but appeared to be associated...
Breaking Medicine News(10 mins):Health News:NIP Acquires San Diego Executive Benefits Firm 2Health News:Marianjoy Medical Group Physician Receives James Brady Award 2Health News:Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3Health News:Advertising to Consumers May Raise Drug Prices 2
... Eli Lilly and Company (NYSE: LLY ) announced t...ommittee for Medicinal Products for Human Use (CHM...IMTA(R) (pemetrexed for injection) as monotherapy ...gy in patients whose disease has not progressed im...
...(May 28, 2009) While minimally invasive coil trea...ve proved to be a more effective technique than tr... the superior procedure is drastically more expens...an 2,000 patients half of whom underwent minimall...
...29 Results of a new study published in the journa... tangible effect on metabolism. , , Researchers f...nter in Lausanne, Switzerland, fed mice two differ...different. , , They also observed that one biol...
...emale Health Company (NYSE Amex: FHC ) announced...e decision to switch the listing of its common sto...et LLC. Effective as of the opening of trading on ...nsideration of capital market alternatives and ana...
...y poses risks for older, poorer people, study find...Living in unsafe neighborhoods -- or even believin...ability among elderly, low-income people, suggests...al or psychological processes," Dr. Cheryl Clark, ...
... the world,s leading Alzheimer,s researchers have ... new developments in the diagnosis and treatment o...imer,s disease conference held in Chile, George Pe...f Chile Medical School have edited " Current Hypot...
Other Medicine News:Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 2Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 3Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 4Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 5Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 6Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 7Health News:Minimally invasive stroke treatment produces better patient outcomes than surgical operation 2Health News:New Study Shows Probiotics Linked to Metabolism 2Health News:The Female Health Company Switches to the NASDAQ Stock Market 2Health News:The Female Health Company Switches to the NASDAQ Stock Market 3Health News:UTSA Dean George Perry co-edits textbook chronicling four decades of Alzheimer's research 2
Albumin (BCG)
ASAT (GOT) FS (IFCC mod.)
AST (GOT) + Starter Reagent
...stem, offers speed and true walk away efficiency i...voirs and 1 drying station can be utilized to give...ams to meet the demands of the lab. Two start stat...rks by automatically picking up each basket set an...
Medicine Products: